Wendy Stock to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications Wendy Stock has written about Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
3.212
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
Score: 0.843
-
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
Score: 0.675
-
"Dar"-ing to target CD38 in T-ALL. Blood. 2018 03 01; 131(9):948-949.
Score: 0.578
-
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL. Leukemia. 2024 03; 38(3):491-501.
Score: 0.216
-
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.
Score: 0.206
-
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 12 01; 107(12):2783-2793.
Score: 0.201
-
Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022 06; 3(6):768-782.
Score: 0.193
-
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299.
Score: 0.177
-
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
Score: 0.122